Vitrolife reported the second quarter results this morning. Sales came in slightly higher than expected, however the OPEX and EO were higher than our forecast, resulting in worse -than-expected EBIT. There are mixed signals in the short term, however the long-term story remains intact and with an ongoing recovery, the total extent of the effect on the second half of the year is still somewhat unclear.  Our fair value remains unchanged at SEK 165 per share even with the lower estimates for 2020. The primary reason is that we still see solid and continuous growth in the years to come and see 2020 as a temporary setback in the growth story.